Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
P/E ratio for Lyra Therapeutics, Inc. (LYRA)
P/E ratio as of 2023: -4.16
According to Lyra Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -4.16. At the end of 2022 the company had a P/E ratio of -1.72.
P/E ratio history for Lyra Therapeutics, Inc. from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -4.16 |
| 2022 | -1.72 |
| 2021 | -1.34 |
| 2020 | -4.44 |
| 2019 | -14.91 |
| 2018 | -19.29 |